Full-Time
Develops vaccines for bacterial infections
$150k - $174k/yr
Senior, Expert
San Carlos, CA, USA
Get referrals →
You have ways to get a Vaxcyte referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 9 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively bypass the complex defenses of bacteria while still provoking an immune response. This method sets Vaxcyte apart from competitors who rely on traditional cell-based vaccine production. The company's goal is to develop broad-spectrum vaccines that can significantly reduce the impact of bacterial diseases on global health.
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Company Equity
Stock Options
Remote Work Options
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.
Vaxcyte aims to develop superior vaccines against bacterial diseases, utilizing advanced synthetic techniques like their XpressCF(TM) cell-free protein synthesis platform.
Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).
In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock